The need for predictive biomarkers of the response to treatments to improve the management of cancers and the introduction of a so-called precision medicine has gradually led the scientific and medical community to consider the value of functional tests carried out ex vivo on tumour samples of different kinds. These functional tests, which enable a dynamic understanding of the response of tumour cells to treatments, may in themselves constitute predictive tests (and therefore be included in the patient management procedure), or allow the identification of subgroups of patients whose response to treatment may be associated with molecular characteristics, which may be predictive biomarkers. These tests require fresh and cultivable tumor material for a long enough time to understand the response to treatments. In this context, the establishment and cultivation of tumour organoids, true miniature tumours whose histological and molecular characteristics are very close to the tumor from which they originate, is particularly attractive and proof of their predictive interest has already been provided in various types of cancers and in relation to various types of treatments.The establishment of tumor organoid culture has recently been initiated in Caen, particularly with a view to improving the management of ovarian cancers. This know-how, unique in Normandy, has gradually led to the implementation of translational protocols addressing other questions from various Norman research teams (PARP inhibitors in breast cancers, radiotherapy in VADS cancers, brain tumours and chondrosarcomas), leading researchers to consider the need to change scale and propose the establishment of a predictive organoid platform (ORGAPRED). This is an ambitious project, supported by the Normandy Regional Council in its first step within the framework of the “Emergence” RIN scheme, aimed at proposing an open platform at regional and then national level and may request an IBISA label, in a coordinated way with the “organoids” working group set up by AVIESAN and in the context of the likely establishment of a national network of organoid platforms. To our knowledge, at present, only the Norman site is organised as an open platform in the field of tumor organoids, making ORGAPRED the first such platform in France.The perspectives of the work on organoids are of several kinds, since they allow in particular:- to predict patients’ response to chemotherapy or radiotherapy treatments (thanks to the possibility of carrying out various functional tests), providing support for the therapeutic decision needed to implement precision medicine protocols;- to identify predictive biomarkers through the use of large organoid panels;- to implement preclinical studies to validate new therapeutic strategies from the research of the units involved;- to develop partnerships with pharmaceutical manufacturers for the accelerated evaluation of developing molecules.These objectives are integrated into the OncoThera² project under preparation (RIN springboard, following the establishment of the Normand Network of Therapeutic Innovation in Oncology (OncoThera) in 2018 and will be integrated into the FHU under preparation by Prof. T. Frebourg and in the RHU “TRESHAD” in preparation by Prof. J. Thariat, himself connected to the archade programme.